Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEVANEC: bevacizumab plus FOLFIRI as second-line treatment for advanced poorly differentiated GEP or unknown-primary neuroendocrine carcinoma
2016-001305-16Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, irinotecan, fluorouracil and folinic acid in neuroendocrine carcinoma (NEC) and gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Proportion of patients alive at 6 months. Started Jul 2017; status: completed.
02
Drugs
bevacizumabirinotecanfluorouracilfolinic acid
03
Conditions
neuroendocrine carcinoma (NEC)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on 2016-001305-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001305-16.